Molidustat (BAY85-3934)Novel HIF-PH inhibitor CAS# 1154028-82-6 |
2D Structure
- CI994 (Tacedinaline)
Catalog No.:BCC2159
CAS No.:112522-64-2
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- LAQ824 (NVP-LAQ824,Dacinostat)
Catalog No.:BCC2160
CAS No.:404951-53-7
- AR-42 (OSU-HDAC42)
Catalog No.:BCC2161
CAS No.:935881-37-1
- TC-H 106
Catalog No.:BCC2426
CAS No.:937039-45-7
- KD 5170
Catalog No.:BCC2420
CAS No.:940943-37-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1154028-82-6 | SDF | Download SDF |
PubChem ID | 59603622 | Appearance | Powder |
Formula | C13H14N8O2 | M.Wt | 314.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | BAY 85-3934 | ||
Solubility | DMSO : 5 mg/mL (15.91 mM; Need ultrasonic) | ||
Chemical Name | 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one | ||
SMILES | C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4 | ||
Standard InChIKey | IJMBOKOTALXLKS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Molidustat (BAY 85-3934) is a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with mean IC50 values of 480 nM for PHD1, 280 nM for PHD2, and 450 nM for PHD3.In Vitro:The mean IC50 values of BAY 85-3934 for PHD1, PHD2, and PHD3 are 480 nM, 280 nM, and 450 nM, respectively. Exposure of HeLa cells to 5 μM BAY 85-3934 for 20 min is sufficient to induce detectable concentrations of HIF-1α. In a cellular reporter assay, BAY 85-3934 induces the expression of the firefly luciferase reporter gene under the control of a hypoxia responsive element promoter at a mean (± SD) EC50 of 8.4±0.7 μM (n=4) [1].In Vivo:HIF stabilization by oral administration of the HIF-PH inhibitor BAY 85-3934 (molidustat) results in dose-dependent production of EPO in healthy Wistar rats and cynomolgus monkeys. Molidustat therapy is aldo effective in the treatment of renal anemia in rats with impaired kidney function and, unlike treatment with rhEPO, resulted in normalization of hypertensive blood pressure in a rat model of CKD[1]. References: |
Molidustat (BAY85-3934) Dilution Calculator
Molidustat (BAY85-3934) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1817 mL | 15.9084 mL | 31.8167 mL | 63.6335 mL | 79.5418 mL |
5 mM | 0.6363 mL | 3.1817 mL | 6.3633 mL | 12.7267 mL | 15.9084 mL |
10 mM | 0.3182 mL | 1.5908 mL | 3.1817 mL | 6.3633 mL | 7.9542 mL |
50 mM | 0.0636 mL | 0.3182 mL | 0.6363 mL | 1.2727 mL | 1.5908 mL |
100 mM | 0.0318 mL | 0.1591 mL | 0.3182 mL | 0.6363 mL | 0.7954 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Molidustat (BAY85-3934)
Description:
IC50: 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively.
Oxygen sensing via hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) is the dominant regulatory mechanism of erythropoietin (EPO) expression. In chronic kidney disease (CKD), impaired EPO expression causes anemia, which can be treated by supplementation with recombinant human EPO (rhEPO). Molidustat (BAY85-3934) is a novel HIF-PH inhibitor.
In vitro: The IC50 values were found to be dependent on the 2-oxoglutarate concentration in the reaction buffer. By lowering the 2-oxoglutarate concentration from 20 μM to 0.3 μM, the potency of the test compound increased up to 10-fold. Variation of the concentrations of Fe2+ and ascorbate in the reaction buffer by factors of 30 and 200, respectively, did not alter the potency of the inhibitor by more than 2-fold [1].
In vivo: In repeat dosing of BAY 85-3934, hemoglobin levels were increased compared with animals in vehicle group, while endogenous EPO remained within the normal physiological range. BAY 85-3934 therapy was also effective in the treatment of renal anemia in rats with impaired kidney function and, unlike treatment with rhEPO, resulted in normalization of hypertensive blood pressure in a rat model of CKD [1].
Clinical trial: Clinical studies are still ongoing to investigate the effects of BAY 85-3934 therapy in patients with renal anemia (https://clinicaltrials.gov/ct2/show/NCT01332942?term=Molidustat&rank=2).
Reference:
[1] Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838.
- EIPA
Catalog No.:BCC7672
CAS No.:1154-25-2
- Kanshone B
Catalog No.:BCN7700
CAS No.:115370-61-1
- 2,2-Dimethyl-6-phenylpyrano[3,4-b]pyran-8-one
Catalog No.:BCN7280
CAS No.:1153624-36-2
- Kanshone A
Catalog No.:BCN7279
CAS No.:115356-18-8
- Siguazodan
Catalog No.:BCC6954
CAS No.:115344-47-3
- NAN-190 hydrobromide
Catalog No.:BCC6693
CAS No.:115338-32-4
- Dihydroniloticin
Catalog No.:BCN6032
CAS No.:115334-05-9
- Phellochin
Catalog No.:BCN6031
CAS No.:115334-04-8
- Isosalvipuberulin
Catalog No.:BCN6030
CAS No.:115321-32-9
- 3-Bromo-N-phenylcarbazole
Catalog No.:BCN2260
CAS No.:1153-85-1
- A 1120
Catalog No.:BCC7775
CAS No.:1152782-19-8
- Dofetilide
Catalog No.:BCC3770
CAS No.:115256-11-6
- Niloticin
Catalog No.:BCN6033
CAS No.:115404-57-4
- Risedronate Sodium
Catalog No.:BCC2501
CAS No.:115436-72-1
- Sootepin D
Catalog No.:BCN6034
CAS No.:1154518-97-4
- Glaucin B
Catalog No.:BCN6035
CAS No.:115458-73-6
- 5,6,7,7a-Tetrahydrothieno[3,2-c]pyridine-2(4H)-one hydrochloride
Catalog No.:BCC8721
CAS No.:115473-15-9
- Z-Glu-OH
Catalog No.:BCC2781
CAS No.:1155-62-0
- H-Lys(Z)-OH
Catalog No.:BCC2986
CAS No.:1155-64-2
- (2-Amino-1-hydroxyethyl)phosphonic acid
Catalog No.:BCN1613
CAS No.:115511-00-7
- Fmoc-Cys(Trt)-Opfp
Catalog No.:BCC3480
CAS No.:115520-21-3
- BI 224436
Catalog No.:BCC5531
CAS No.:1155419-89-8
- Marbofloxacin
Catalog No.:BCC2510
CAS No.:115550-35-1
- Marbofloxacin hydrochloride
Catalog No.:BCC4250
CAS No.:115551-26-3